Sermorelin GHRH (1-29)
Synonyms: GRF 1-29
CAS Number: 86168-78-7
Molar mass: 3357.882 g/mol
sermorelin powder: 1grams/bag
sermorelin injections:10mg in 2cc vial,10mg/vial, 10 vials/kit
storaqge:protect sun damage and 2-8 degrees Celsius
Sermorelin (INN), also known as GHRH (1-29), is a growth hormone-releasing hormone (GHRH) analogue used as a diagnostic agent. It is a 29-amino acid polypeptide representing the 1-29 fragment from endogenous human GHRH, and is thought to be the shortest fully functional fragment of GHRH. It is used as a diagnostic agent to assess growth hormone (GH) secretion.
Sermorelin is available in varying milligram dosages, A dosage of 0.2 - 0.3 mcg of sermorelin acetate once daily at bedtime by subcutaneous injection is recommended.Sermorelin is officially indicated and approved for diagnostic evaluation of pituitary function and also for increasing growth in children. Sermorelin has many off label usages including acute or age-related growth hormone insufficiency such as dwarfism, as well as in the prevention of HIV-induced weight loss. It works by increasing plasma growth hormone (GH) concentrations through stimulating the pituitary gland to release GH. More specifically, Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.
Effect of Sermorelin
Changes in body composition
bone mineral density
The Sermorelin Acetate Peptide and HGH
Sermorelin Acetate, which shares similar structure to CJC-1295, is a bio-identical synthetic hormone that is extremely effective in increasing the amount of HGH. Human Growth Hormone is a hormone released by the body that controls the reproduction and growth of the cells and each of the organs in the body. At a young age, the body's HGH production is most active while the growth rate is at its highest point. After the age of 30, for every decade of life, there is a 14% reduction in HGH production . By the age of 40, HGH production is about 40 percent of what it was at the age of 20. With the further development of Growth Hormone Releasing Factors (GHRF), such as Modified GRF 1-29, HGH production may possibly begin again by stimulating the pituitary gland.